Recent advances in systemic treatments for ovarian cancer

被引:9
|
作者
Banerjee, Susana [1 ]
Gore, Martin [1 ]
机构
[1] Royal Marsden NHS Fdn Trust, Gynaecol Unit, London, England
来源
CANCER IMAGING | 2012年 / 12卷 / 02期
关键词
Ovarian cancer; chemotherapy; targeted therapy; bevacizumab; PARP inhibitors; PHASE-III TRIAL; RECURRENT EPITHELIAL OVARIAN; PLATINUM-BASED CHEMOTHERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; PLUS CARBOPLATIN; RANDOMIZED-TRIAL; INTRAPERITONEAL CISPLATIN; PRIMARY PERITONEAL; INTERGROUP TRIAL; STAGE-III;
D O I
10.1102/1470-7330.2012.9002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer remains the leading cause of death from gynaecological cancer. Advances in surgical and chemotherapeutic strategies have led to improvements in outcome. However, the majority of women present with advanced disease with little prospect for cure. In this article, we summarize the systemic management and ovarian cancer and raise a number of important issues: namely the timing of systemic therapy in relation to surgery, the selection of patients who do not require systemic therapy and the development of novel agents.
引用
收藏
页码:305 / 309
页数:5
相关论文
共 50 条
  • [21] Achievements and unmet needs in the management of advanced ovarian cancer
    Guarneri, Valentina
    Piacentini, Federico
    Barbieri, Elena
    Conte, Pier Franco
    GYNECOLOGIC ONCOLOGY, 2010, 117 (02) : 152 - 158
  • [22] Advances in ovarian cancer therapy
    Cortez, Alexander J.
    Tudrej, Patrycja
    Kujawa, Katarzyna A.
    Lisowska, Katarzyna M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (01) : 17 - 38
  • [23] Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer - ESMO-MCBS scores
    Broekman, K. E.
    Jalving, M.
    van Tinteren, H.
    Sessa, C.
    Reyners, A. K. L.
    CANCER TREATMENT REVIEWS, 2018, 69 : 233 - 242
  • [24] GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012
    Gonzalez Martin, A.
    Redondo, A.
    Jurado, M.
    De Juan, A.
    Romero, I.
    Bover, I.
    Del Campo, J. M.
    Cervantes, A.
    Garcia, Y.
    Lopez-Guerrero, J. A.
    Mendiola, C.
    Palacios, J.
    Rubio, M. J.
    Poveda Velasco, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (07) : 509 - 525
  • [25] Immunotherapy for ovarian cancer: recent advances and perspectives
    Zsiros, Emese
    Tanyi, Janos
    Balint, Klara
    Kandalaft, Lana E.
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (05) : 492 - 500
  • [26] Is there a current change of maintenance treatment in ovarian cancer? An updated review of the literature
    Sakarya, Derya Kilic
    Yetimalar, Mehmet Hakan
    JOURNAL OF BUON, 2016, 21 (02): : 290 - 300
  • [27] Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores
    Broekman, K. E.
    Van Kruchten, M.
    Van Tinteren, H.
    Sessa, C.
    Jalving, M.
    Reyners, A. K. L.
    ESMO OPEN, 2021, 6 (04)
  • [28] Recent advances in systemic therapy Advances in adjuvant systemic chemotherapy of early breast cancer
    Lopez-Tarruella, Sara
    Martin, Miguel
    BREAST CANCER RESEARCH, 2009, 11 (02)
  • [29] Recent Developments in Combinatorial Immunotherapy towards Ovarian Cancer
    Jain, Chakresh Kumar
    Kulshreshtha, Aishani
    Saxena, Harshita
    Agarwal, Avinav
    Passi, Kalpdrum
    CURRENT WOMENS HEALTH REVIEWS, 2024, 20 (04) : 6 - 19
  • [30] Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer
    Bouberhan, Sara
    Pujade-Lauraine, Eric
    Cannistra, Stephen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27) : 2424 - +